Clinical experiences with tolterodine.
Tolterodine is the first muscarinic receptor antagonist that has been specifically developed for the treatment of overactive bladder. The objectives in the discovery program were to design a potent muscarinic receptor antagonist that is equipotent to oxybutynin in the bladder, but less potent in salivary glands, with the aim of improving tolerability (less dry mouth) in patients with overactive bladder. Tolterodine is non-selective with respect to the muscarinic M1-M5 receptor subtypes, but has a greater effect on the bladder than on salivary glands in vivo, in both animals and humans. Clinical results show that the efficacy and safety of tolterodine in overactive bladder is equal to that of oxybutynin, but that tolterodine is significantly better tolerated by the patients.
Nilvebrant
L
L
Bioventia Life Science Consultants c/o Nilvebrant Pharma Consulting AB, Bromma, Sweden. lisbeth.nilvebrant@bioventia.com
D000818:Animals; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003408:Cresols / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D010665:Phenylpropanolamine; D011788:Quality of Life; D000068737:Tolterodine Tartrate; D001743:Urinary Bladder / Q000187:drug effects*; D001745:Urinary Bladder Diseases / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D003408:Cresols; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin